Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Benatar

Showing results (231-240 of 242) with videos related to

Pageof 25
Sort By:
JAMA Neurology|February 3, 2015
A genome-wide association study of myasthenia gravisAlan E Renton, Hannah A Pliner, Carlo Provenzano, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 19, 2021
Preface: promoting research in PLS: current knowledge and future challengesHiroshi Mitsumoto, Martin R Turner, , et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 4, 2013
ALS Untangled No. 20: the Deanna protocol, Christina Fournier, Bedlack Bedlack, et al.
Neuron|September 28, 2011
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTDAlan E Renton, Elisa Majounie, Adrian Waite, et al.
JAMA Neurology|February 18, 2020
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical TrialJames F Howard, Richard J Nowak, Gil I Wolfe, et al.
Science Translational Medicine|March 31, 2017
Poly(GP) proteins are a useful pharmacodynamic marker for <i>C9ORF72</i>-associated amyotrophic lateral sclerosisTania F Gendron, Jeannie Chew, Jeannette N Stankowski, et al.
JAMA Network Open|February 17, 2025
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical TrialSabrina Paganoni, Christina N Fournier, Eric A Macklin, et al.
JAMA|March 11, 2025
CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial, James D Berry, Nicholas J Maragakis, et al.
JAMA Neurology|March 11, 2025
Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial, Jinsy Andrews, Sabrina Paganoni, et al.
JAMA|March 11, 2025
Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial, Jeremy M Shefner, Björn Oskarsson, et al.
Pageof 25

Showing results (231-240 of 242) with videos related to

Sort By:
Pageof 25
JAMA Neurology|February 3, 2015
A genome-wide association study of myasthenia gravisAlan E Renton, Hannah A Pliner, Carlo Provenzano, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 19, 2021
Preface: promoting research in PLS: current knowledge and future challengesHiroshi Mitsumoto, Martin R Turner, , et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 4, 2013
ALS Untangled No. 20: the Deanna protocol, Christina Fournier, Bedlack Bedlack, et al.
Neuron|September 28, 2011
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTDAlan E Renton, Elisa Majounie, Adrian Waite, et al.
JAMA Neurology|February 18, 2020
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical TrialJames F Howard, Richard J Nowak, Gil I Wolfe, et al.
Science Translational Medicine|March 31, 2017
Poly(GP) proteins are a useful pharmacodynamic marker for <i>C9ORF72</i>-associated amyotrophic lateral sclerosisTania F Gendron, Jeannie Chew, Jeannette N Stankowski, et al.
JAMA Network Open|February 17, 2025
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical TrialSabrina Paganoni, Christina N Fournier, Eric A Macklin, et al.
JAMA|March 11, 2025
CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial, James D Berry, Nicholas J Maragakis, et al.
JAMA Neurology|March 11, 2025
Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial, Jinsy Andrews, Sabrina Paganoni, et al.
JAMA|March 11, 2025
Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial, Jeremy M Shefner, Björn Oskarsson, et al.
Pageof 25